Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized pivotal clinical study of nadunolimab (CAN04) in patients with advanced pancreatic cancer (PDAC)

Next Previous
X
Search
Trial Profile

A randomized pivotal clinical study of nadunolimab (CAN04) in patients with advanced pancreatic cancer (PDAC)

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 10 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nadunolimab (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 08 Apr 2024 According to a Cantargia media release, Cantargia is preparing a phase IIb clinical trial in first line PDAC with a planned start during summer 2024.
    • 18 Jul 2022 According to a Cantargia media release, the company has announced rights issue to secure financing to fund preparations of this trial.
    • 08 Jul 2022 According to a Cantargia media release, the company expect to start this tri lain 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top